CMH :: Clinical and Molecular Hepatology

Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries

KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef

Drug Discovery Study Aimed at a Functional Cure for HBV

Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile

Sheng-Jie Shiue, Chao-Ling Cheng, Han-Shiang Shiue, Chun-Nan Chen, Sheng-Wei Cheng, Li-Wei Wu, Ganbolor Jargalsaikhan, Tze-Sian Chan, Hsin-Yi Lin, Ming-Shun Wu

Long‐term clinical outcome of HBeAg‐negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues

Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie‐Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis

Advances in treatment and prevention of hepatitis B

Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav

World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis

Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson

Advances in treatment and prevention of hepatitis B

Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav

World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

Hepatology Communications.2021; 5(10): 1632. CrossRef

Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B

Do Seon Song, Jeong Won Jang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

Clinical Infectious Diseases.2021; 73(4): e892. CrossRef

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy

Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee

Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections

Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao

Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg‐negative chronic hepatitis B

Hariklia Kranidioti, Spilios Manolakopoulos, George Kontos, Michael S. Breen, Anastasia Kourikou, Melanie Deutsch, Maria Ester Quesada‐Del‐Bosque, Rocio T. Martinez‐Nunez, Mohammed M. Naiyer, Christopher H. Woelk, Tilman Sanchez‐Elsner, Emilia Hadziyannis

Journal of Viral Hepatitis.2019; 26(6): 697. CrossRef

KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef

Lung-Yi Mak, Wai-Kay Seto, James Fung, Man-Fung Yuen

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

An expert consensus for the management of chronic hepatitis B in Asian Americans

M. J. Tong, C. Q. Pan, S.‐H. B. Han, D. S.‐K. Lu, S. Raman, K.‐Q. Hu, J. K. Lim, H. W. Hann, A. D. Min

Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181. CrossRef